Group 1 - AbbVie will announce its full-year and fourth-quarter 2025 financial results on February 4, 2026, before the market opens [1] - A live webcast of the earnings conference call will be hosted at 8 a.m. Central time, accessible through AbbVie's Investor Relations website [1] - An archived edition of the earnings call will be available later on the same day [1] Group 2 - AbbVie's mission focuses on discovering and delivering innovative medicines and solutions for serious health issues, addressing both current and future medical challenges [2] - The company aims to have a significant impact across key therapeutic areas, including immunology, oncology, neuroscience, and eye care, as well as in its Allergan Aesthetics portfolio [2] - Additional information about AbbVie can be found on its official website and social media platforms [2]

Core Viewpoint - Gilead Sciences, Inc. (GILD) is initiated with a Strong Buy rating and a price target of $181, focusing on its transformative therapies in HIV, viral hepatitis, oncology, and other unmet medical needs globally [1]. Group 1: Company Overview - Gilead is engaged in the discovery, development, and commercialization of therapies that address significant medical needs [1]. - The company operates in various therapeutic areas, including HIV, viral hepatitis, and oncology, indicating a diversified portfolio [1]. Group 2: Research Methodology - Moretus Research employs a structured, repeatable framework to identify companies with durable business models and mispriced cash flow potential [1]. - The research emphasizes rigorous fundamental analysis combined with a judgment-driven process, focusing on clarity and actionable insights [1]. - Valuation methods are based on sector-relevant multiples tailored to each company's business model, ensuring comparability and relevance [1]. Group 3: Investment Philosophy - Moretus Research targets underappreciated companies undergoing structural changes or temporary dislocations, where disciplined analysis can yield asymmetric returns [1]. - The research aims to elevate the standard for independent investment research by providing professional-grade insights and a strong filter for essential information in equity analysis [1].